Skip to main content

Peer Review reports

From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Original Submission
28 Feb 2018 Submitted Original manuscript
23 May 2018 Author responded Author comments - Angelo Camporeale
14 Apr 2018 Reviewed Reviewer Report - Randolph Evans
19 Apr 2018 Reviewed Reviewer Report - Hans-Christoph Diener
24 Apr 2018 Reviewed Reviewer Report - Pierangelo Geppetti
Resubmission - Version 2
23 May 2018 Submitted Manuscript version 2
10 Sep 2018 Author responded Author comments - Angelo Camporeale
12 Jun 2018 Reviewed Reviewer Report - Hans-Christoph Diener
Resubmission - Version 3
10 Sep 2018 Submitted Manuscript version 3
26 Oct 2018 Author responded Author comments - Angelo Camporeale
Resubmission - Version 4
26 Oct 2018 Submitted Manuscript version 4
Publishing
31 Oct 2018 Editorially accepted
9 Nov 2018 Article published 10.1186/s12883-018-1193-2

You can find further information about peer review here.

Back to article page
\